Intec Pharma begins clinical development of Accordion Pill for …

Intec Pharma Ltd, a clinical stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology, announced the initiation of a new clinical development programme for its Accordion Pill platform with the two primary cannabinoids contained in Cannabis sativa. Intec Pharma plans to formulate and test Cannabidiol (CBD) and Tetrahydrocannabinol (THC), or AP-CBD/THC, for the treatment of various indications, including pain management. The company plans to initiate a phase I clinical trial with AP-CBD/THC during the first quarter of 2017.

Clinical testing by others appears to indicate that extracts of the Cannabis sativa plant containing known amounts of the active compounds (mainly THC and CBD) or diverse synthetic derivatives of THC are promising treatments

... read more at: